Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Luye Selects AstraZeneca to Market its Anti-Cholesterol Drug in China

publication date: Jan 16, 2019

Luye Pharma out-licensed mainland China marketing rights for its anti-cholesterol Xuezhikang capsules to AstraZeneca China. Xuezhikang is a fermented form of red yeast rice that is similar to a statin. It has successfully completed US Phase II trials, and the two companies are considering expanding distribution to the US, Europe and emerging markets. They expect Xuezhikang revenues will continue growing at a double-digit rate. The partnership is the first time a China biopharma has partnered China product rights with a multinational company for a product it developed. More details....

Stock Symbols: (HK_8126) (NYSE: AZN)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.